Vitamin C: Intravenous use by complementary and alternative medicine practitioners and adverse effects

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Padayatty, Sebastian J ^a   Sun, Andrew Y ^a   Chen, Qi ^b   Espey, Michael Graham ^a   Drisko, Jeanne ^b   Levine, Mark ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID;

ALTERNATIVE MEDICINE; ARTICLE; BREAST CANCER; COLON CANCER; COMMON COLD; CONTINUOUS INFUSION; DRUG ADMINISTRATION ROUTE; DRUG FATALITY; DRUG INDICATION; DRUG MARKETING; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HEMOLYSIS; HEPATITIS; HUMAN; INFLUENZA; INJECTION SITE IRRITATION; INJECTION SITE PHLEBITIS; KIDNEY DISEASE; KIDNEY FAILURE; LETHARGY; LOW DRUG DOSE; LUNG CANCER; LYME DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MENTAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; OVARY CANCER; PRESCRIPTION; PROSTATE CANCER; TREATMENT RESPONSE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; INFORMATION PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY;

ASCORBIC ACID; COMPLEMENTARY THERAPIES; DATA COLLECTION; HUMANS; INJECTIONS, INTRAVENOUS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77955349971     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011414     Document Type: Article

References (51)

1. Nutrition Business Journal (2008) NBJ's Supplement Business Report 2008: An Analysis of Markets, Trends, Competition and Strategy in the U.S. Dietary Supplement Industry. Figure 3-33(Table 1); Figure 4-18. BoulderCO: Penton Media INC. Lifestyle Division. New Hope Natural Media.
2. Klenner FR (1949) The treatment of poliomyelitis and other virus diseases with vitamin C. South Med Surg 111: 209-14.
3. Klenner FR (1951) Massive doses of vitamin C and the virus diseases. South Med Surg 113: 101-7.
4. Calleja HB, Brooks RH (1960) Acute hepatitis treated with high doses ofvitamin C. Report of a case. Ohio Med 56: 821-23.
5. Klenner FR (1971) Observations on the dose and administration ofascorbic acid when employed beyond the range of a vitamin in human pathology. Journal of Applied Nutrition 23: 61-88.
6. Cathcart RF (1891) Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy. Med Hypotheses 7: 1359-76.
7. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA(1995) Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 44: 207-13.
8. Pauling L (1976) Vitamin C the common cold and the flu. San Francisco: W.H.Freeman and Co.
9. Cameron E, Pauling L (1976) Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73: 3685-89.
10. Cameron E, Pauling L (1978) Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75: 4538-42.
11. Riordan NH, Riordan HD, Casciari JJ (2000) Clinical and experimental experiences with intravenous vitamin C.J Orthomolecular Med 15: 201-3.
12. Levy TE (2002) Vitamin C, Infectious Diseases, and Toxins: Curing the Incurable. Philadelphia: Xlibris.
13. Gonzalez MJ, Miranda-Massari JR, Mora EM, Guzman A, Riordan NH, Riordan HD, et al. (2005) Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther 4: 32-44.
14. Levine M, Espey MG, Chen Q(2009) Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment. Free Radic Biol Med 47: 27-29.
15. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, et al. (2004) Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140: 533-37.
16. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, et al. (2008) Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19: 1969-74.
17. Padayatty SJ, Levine M (2000) Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr 19: 423-25.
18. Chen Q Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, et al. (2005) Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 102: 13604-9.
19. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, et al. (2007) Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A 104: 8749-54.
20. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, et al. (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105: 11105-9.
21. Verrax J, Calderon PB (2009) Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47: 27-9.
22. Lawton JM, Conway LT, Crosson JT, Smith CL, Abraham PA (1985) Acute oxalate nephropathy after massive ascorbic acid administration. Arch Intern Med 145: 950-951.
23. Wong K, Thomson C, Bailey RR, McDiarmid S, Gardner J (1994) Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z J Med 24: 410-411.
24. McAllister CJ, Scowden EB, Dewberry FL, Richman A (1984) Renal failure secondary to massive infusion of vitamin C. JAMA 252: 1684.
25. Campbell GD, Jr., Steinberg MH, Bower JD (1975) Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med 82: 810.
26. Rees DC, Kelsey H, Richards JD (1993) Acute haemolysis induced by high dose ascorbic acid in glucose-6- phosphate dehydrogenase deficiency. BMJ 306: 841-42.
27. Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complementary and alternative medicine use among adults: United States 2002. Adv Data. 1-19.
28. Gaby AR (2002) Intravenous nutrient therapy: the ''Myers' cocktail''. Altern Med Rev 7: 389-403.
29. Ali A, Njike VY, Northrup V, Sabina AB, Williams AL, Liberti LS, et al. (2009) Intravenous micronutrient therapy (Myers' Cocktail) for fibromyalgia: a placebo-controlled pilot study. JAltern Complement Med 15: 247-57.
30. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y (1999) Criteria and recommendations for vitamin C intake. JAMA 281: 1415-23.
31. Jungeblut CW (1935) Inactivation of poliomyelitis virus in vitro by crystalline vitamin C (ascorbic acid). Journal of Experimental Medicine 62: 517-21.
32. Jungeblut CW (1937) Further observations on vitamin C therapy in experimental poliomyelitis. Journal of Experimental Medicine 66: 459-77.
33. Sabin AB (1939) Vitamin C in relation to experimental poliomyelitis. Journal of Experimental Medicine 69: 507-16.
34. Jungeblut CW (1939) A further contribution to vitamin C therapy in experimental poliomyelitis. Journal of Experimental Medicine 70: 315-32.
35. Riordan HD, Jackson JA, Schultz M (1990) Case study: high-dose intravenous vitamin C in the treatment of a patient with adenocarcinoma of the kidney. J Orthomolecular Med 5: 5-7.
36. McCormick WJ (1954) Cancer: the preconditioning factor in pathogenesis; a new etiologic approach. Arch Pediatr 71: 313-22.
37. Cameron E, Rotman D (1972) Ascorbic acid, cell proliferation, and cancer. Lancet 1: 542.
38. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM (1985) High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl JMed 312: 137-41.
39. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, et al. (1979) Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl JMed 301: 687-90.
40. Wittes RE (1985) Vitamin C and cancer. N Engl JMed 312: 178-79.
41. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, et al. (1996) Vitamin C pharmacokinetics in healthy volunteers: evidence for a Recommended Dietary Allowance. Proc Natl Acad Sci U S A 93: 3704-9.
42. Levine M, Wang Y, Padayatty SJ, MorrowJ (2001) A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 98: 9842-46.
43. Padayatty SJ, Levine M (2006) Vitamins C and E and the prevention of preeclampsia. N EnglJ Med 355: 1065.
44. Canavese C, Petrarulo M, Massarenti P, Berutti S, Fenoglio R, Pauletto D, et al. (2005) Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis 45: 540-549.
45. Pena dl V, Lieske JC, Milliner D, GonyeaJ, Kelly DG (2004) Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose. JPENJ Parenter Enteral Nutr 28: 435-38.
46. Iwamoto N, Kawaguchi T, Horikawa K, Nagakura S, Hidaka M, Kagimoto T, et al. (1994) Haemolysis induced by ascorbic acid in paroxysmal nocturnal haemoglobinuria. Lancet 343: 357.
47. Iwamoto N, Nakakuma H, Ota N, Shimokado H, Takatsuki K (1994) Ascorbic acid-induced hemolysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Am JHematol 47: 337-38.
48. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, et al. (2008) Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68: 8031-38.
49. Patterson JW (1950) The diabetogenic effect of dehydroascorbic and dehydroisoascorbic acids. JBiol Chem 183: 81-88.
50. Patterson JW (1951) Course of diabetes and development of cataracts after injecting dehydroascorbic acid and related substances. AmJ Physiol 165: 61-65.
51. Bromley J, Hughes BG, Leong DC, Buckley NA (2005) Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. Ann Pharmacother 39: 1566-69.